Arthur Przybyl - ANI Pharmaceuticals Insider

ANI Pharmaceuticals -- USA Stock  

USD 59.97  0.67  1.10%

CEO and President and Director

Mr. Arthur S. Przybyl is President, Chief Executive Officer, Director of the Company
Age: 59  CEO Since 2013      
Przybyl is an experienced healthcare executive in a career that spans over 25 years and includes the management of both specialty pharmaceutical and medical device companies. From August 2002 through January 2009, Mr. Przybyl served as President and Chief Executive Officer of Akorn, Inc., a NASDAQlisted specialty pharmaceutical company that manufactures and markets ophthalmic, liquid and lyophilized injectable, and vaccine drug products. Prior to Akorn, Mr. Przybyl was President of privatelyheld company Hearing Innovations, Inc. and President and Chief Operating Officer of NASDAQlisted company Bioject, Inc., both of which are medical device companies. During his career, Mr. Przybyl has held several sales and marketing management positions, including Senior Vice President, Sales and Marketing for International Medication Systems, Inc. and Director, Corporationrationrationrate Marketing and National Accounts for LyphoMed, Inc., both specialty pharmaceutical companies.

Arthur Przybyl Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of 6.74 % which means that it generated profit of $6.74 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of (0.63) % meaning that it created substantial loss on money invested by shareholders.
The company currently holds 201.51 M in liabilities with Debt to Equity (D/E) ratio of 115.3 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. ANI Pharmaceuticals has Current Ratio of 3.29 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Found 4 records

CEO Since

Ryan WattsDenali Therapeutics
Barry SimonNantKwest
Douglas FambroughDicerna Pharmaceuticals
Jeffrey BachaDelMar Pharmaceuticals

Entity Summary

ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States. ANI Pharmaceuticals, Inc. is headquartered in Baudette, Minnesota. ANI Pharmaceuticals operates under Biotechnology classification in USA and traded on NASDAQ General Markets. It employs 173 people.ANI Pharmaceuticals (ANIP) is traded on NASDAQ General Markets in USA. It is located in MINNESOTA, U.S.A and employs 173 people. ANI Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification.

ANI Pharmaceuticals Leadership Team

Robert Brown, Chairman, MBA
Charlotte Arnold, President, MBA
Mark Ginski, President, Ph.D
Robert Schrepfer, VP, MBA
Daniel Raynor, Director
Stephen Carey, President
David Sullivan, VP, Ph.D
Karen Quinn, President
James Marken, VP
Peter Lankau, Director
Fred Holubow, Director
Tracy Marshbanks, Director
Arthur Przybyl, CEO
Thomas Penn, Director

Stock Performance Indicators

Current Sentiment - ANIP

ANI Pharmaceuticals Investor Sentiment
Most of Macroaxis users are presently bullish on ANI Pharmaceuticals. What is your sentiment towards investing in ANI Pharmaceuticals? Are you bullish or bearish?
98% Bullish
2% Bearish

BATS Exchange Efficient Frontier

Diversify in USA Market
The main assumption in equity investing is that a higher degree of volatility (or risk) means a higher potential (or expected) return on investment. Conversely, investors who take on a low degree of risk have a low expection for return.
Diversify Portfolios
You can create optimal portfolios in USA market or optimize your existing portfolio in one of two ways: 1) For any level of risk, select the one which has the highest expected return. 2) For any expected return, select the one which has the lowest volatility.
Diversify Portfolios
Check also Trending Equities. Please also try Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.